MedPath

Piclidenoson

Generic Name
Piclidenoson
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H19IN6O4
CAS Number
152918-18-8
Unique Ingredient Identifier
30679UMI0N
Background

CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors.

CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.

Indication

Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis.

Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News
stocktitan.net
·

Can-Fite's Namodenoson Shows Groundbreaking 8-Year Cancer-Free Result in Liver Cancer Patient

Can-Fite BioPharma's Namodenoson, in Phase 3 trials for liver cancer, shows dual benefits: anti-cancer and liver-protective effects via adiponectin. A patient remains cancer-free for over 8 years. Data to be presented at ASCO 2025.
biospace.com
·

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being ...

A patient treated with Namodenoson in Can-Fite's Phase II Liver Cancer Study has shown an 8-year overall survival with complete response. Namodenoson, with Orphan Drug and Fast Track status, is now in a pivotal Phase III study for advanced HCC, aiming to prolong survival. The drug's unique action against tumor cells while protecting normal liver cells underpins the trial's rationale.
biospace.com
·

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Vetbiolix reported positive final results from a canine osteoarthritis study using Piclidenoson, leading to a $325M full license deal with Can-Fite BioPharma. The study demonstrated significant improvement in clinical status and pain reduction with the 500 µg/kg dose, addressing a market projected to reach $3 billion by 2028.
dvm360.com
·

Clinical trial shows promising results for canine osteoarthritis treatment

Can-Fite BioPharma's veterinary collaborator, Vetbiolix, achieved positive final results from a multicenter trial on Piclidenoson for dog osteoarthritis, meeting primary and secondary endpoints. Vetbiolix plans to move forward with an in-license agreement, potentially generating $325 million for Can-Fite over 10 years.
stocktitan.net
·

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred ...

Can-Fite BioPharma Ltd. (CANF) develops oral therapeutics targeting A3AR for cancer, liver, and inflammatory diseases. Key drugs include Piclidenoson (Phase III psoriasis) and Namodenoson (Phase III HCC, Phase IIb NASH). Based in Israel, the company leverages partnerships to advance drug development.
morningstar.com
·

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite BioPharma's Namodenoson granted Orphan Drug Designation by FDA for pancreatic cancer, with plans to start Phase II study by year-end.
globenewswire.com
·

Plaque Psoriasis Drug Forecast and Market Analysis to 2030

The updated 'Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis' report projects the global PsO market to grow from $11.6 billion in 2020 to $31.7 billion by 2030, driven by increased prevalence and new drug launches like SAR44156 and JNJ-2113. Key barriers include patent expirations and legislation aimed at reducing drug prices.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy